The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE
申请人:Calithera Biosciences, Inc.
公开号:US20150004134A1
公开(公告)日:2015-01-01
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
Treatment of lung cancer with inhibitors of glutaminase
申请人:Calithera Biosciences, Inc.
公开号:US10441587B2
公开(公告)日:2019-10-15
The invention relates to methods of treating lung cancer using glutaminase inhibitors. In particular, results demonstrate that lung cancers characterized by an EGFR or KRAS mutation are treated by glutaminase inhibitors.